Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Cardiovascular disease remains a leading cause of mortality worldwide.
• Identifying effective pharmacological interventions for primary and secondary prevention is crucial.
• Gastrointestinal adverse effects of aspirin can limit its use.

Purpose of the Study:

• To evaluate the efficacy of aspirin in primary prevention of myocardial infarction.
• To assess the impact of aspirin on overall mortality.
• To determine the role of ticlopidine and clopidogrel in secondary prevention for peripheral arterial disease.

Main Methods:

• Review of clinical trials assessing aspirin for myocardial infarction risk and mortality.
• Analysis of studies investigating ticlopidine and clopidogrel in patients with symptomatic lower-limb arterial disease.

Main Results:

• Aspirin use was associated with reduced myocardial infarction risk in men over 40 without prior cardiovascular disease and in hypertensive patients.
• Aspirin did not significantly reduce overall mortality.
• Gastrointestinal adverse effects were noted as a significant drawback.
• Ticlopidine and clopidogrel demonstrated a reduction in coronary events for patients with symptomatic lower-limb arterial disease.

Conclusions:

• The risk-benefit ratio of aspirin for primary prevention is questionable due to adverse effects and lack of mortality benefit.
• Antiplatelet agents like ticlopidine and clopidogrel are beneficial for secondary prevention in patients with symptomatic lower-limb arterial disease, reducing coronary event risk.